Patent ID: 11883430
Assignee: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. An ex vivo method for producing hybrid Th1/Th17 and/or Tc1/Tc17 cells comprising:
(a) obtaining a starting population of T cells comprising CD4+ and CD8+ T cells; and
(b) culturing the starting population of T cells in the presence of recombinant IL6, IL1β, IL23, TGFβ and IL-12, thereby differentiating the starting population of T cells to hybrid Th1/Th17 and/or Tc1/Tc17 cells,, wherein the TGFβ is present at a concentration of 0.1 to 0.5 ng/mL, the IL1β, IL23, IL6, and IL12 are each present at a concentration of 5 to 30 ng/mL.